Lantheus is expanding its holdings of PET imaging agents for Alzheimer’s disease, with the acquisition of Meilleur Technologies. The deal grants Lantheus exclusive worldwide rights to Meilleur’s radiopharmaceutical diagnostic that highlights beta amyloid plaques in the brain. The injectable agent—known as NAV-4694, or F18-flutafuranol—is currently in phase 3 development. The acquisition comes just days after the Centers for Medicare and Medicaid Services proposed a separate payment pathway for certain diagnostic radiopharmaceuticals and nuclear medicine imaging agents—instead of bundling them as part of the procedure, as it had in the past.
Read the full article: Lantheus Acquires Alzheimer’s PET Diagnostic Developer Meilleur Technologies //
Source: https://www.fiercebiotech.com/medtech/lantheus-acquires-alzheimers-pet-diagnostic-developer-meilleur-technologies